• Internal Control Solutions:

    Stroomlijnt de documentatie van processen, risico’s en beheersmaatregelen en biedt het management inzicht via rapporten, dashboards, what-if simulaties en verbeterplannen.

    see_movie_on

  • IT-GRC Solutions:

    Al uw IT-gerelateerde processen kunnen worden beheerd met behulp van IT-GRC modules zoals COBIT, Informatiebeveiliging en Bedrijfscontinuïteitsmanagement.

    see_movie_on

  • Risk Management Solutions:

    Eenvoudig risico’s identificeren, analyseren en managen. Geeft het management inzicht via rapporten, dashboards, heat-maps, what-if simulaties en verbeterplannen.

    see_movie_on

  • Internal Audit Solutions:

    Ondersteund de auditcyclus door auditplannen te ontwerpen en beheren, veldwerk en auditevaluaties uit te voeren en auditrapportage te publiceren.

    see_movie_on

  • Open GRC Framework Solutions:

    Ontwerp uw eigen geïntegreerde risico en/of compliance raamwerken.

    Contact us

May 22, 2008

Sigma Tau pharmaceutical selects Dynasec’s easy2comply.com service for its SOX compliance

 


Yokneam, Israel – May 22, 2008 – Dynasec Ltd, a global provider of on-demand software as a service (SaaS) for Governance, Risk and Compliance announced today that Sigma Tau Pharmaceuticals, a company focused on creating therapies for rare diseases has chosen Dynasec’s easy2comply.com on-demand software to manage its compliance with Sarbanes-Oxley.

Like many other corporations that are not strictly obligated to undergo SOX compliance, Sigma Tau decided to voluntarily begin the process of managing their risks and controls in conformance with Sarbanes Oxley.

After several months of evaluating different software solutions, Sigma Tau selected Dynasec’s easy2comply.com. “We were impressed with the functionality of the software solution and SOX know-how of the Dynasec team,” says Don DeLillo, Director of Finance of Sigma Tau, “and also liked the business model of software on-demand which allows us to pay per usage with no long-term commitment or IT integration hassles.”

About Sigma-Tau Pharmaceuticals, Inc.

Sigma-Tau Pharmaceuticals, Inc. is a U.S. based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare ("Orphan") diseases. Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland. The Sigma-Tau Group is a privately held, research focused pharmaceutical company headquartered in Pomezia (Rome), Italy, with subsidiaries in France, Switzerland, the Netherlands, Portugal, Germany, Spain, and the U.S. Employing 2,400 people worldwide (400 in R&D), the Sigma-Tau Group focuses on several therapeutic areas, including cardiovascular, metabolism, central and peripheral nervous system, immunology and oncology, with a portfolio comprising 48projects and clinical trials currently being conducted in 32 different indications. Company website: www.sigmatau.com